PURPOSE: To characterize response shift effects in patients with breast cancer (BC). METHODS: The QLQ-C30, BR23, and EurQOL-EQ-5D were assessed at baseline and at the end of the first hospitalization. We used the then-test approach to characterize changes in internal standards by calculating the mean difference between the then-test (retrospective measure) and pre-test baseline QoL assessments. The Ideal Scale Approach was also used to assess changes in standards by comparing health and QoL expectancies between baseline and the end of the first hospitalization. Successive Comparison Approach was used to assess changes in values through the longitudinal assessment of the relative importance of EuroQOL dimensions. RESULTS: The results of this study showed that recalibration RS effects occurred early after the first hospitalization for 6/15 dimensions of QLQ-C30 (emotional, cognitive, fatigue, insomnia, appetite loss, diarrhea) and 2/8 of BR-23 (future perspective, systemic therapy side effects). Moreover, health and QoL expectancies changed between the baseline and the end of the first hospitalization, and changes in values were seen for the self-care and usual activities dimensions of the EuroQOL-EQ-5D. CONCLUSIONS: The occurrence of RS early after the first hospitalization suggests that it needs to be taken into account to interpret QoL changes in BC.
PURPOSE: To characterize response shift effects in patients with breast cancer (BC). METHODS: The QLQ-C30, BR23, and EurQOL-EQ-5D were assessed at baseline and at the end of the first hospitalization. We used the then-test approach to characterize changes in internal standards by calculating the mean difference between the then-test (retrospective measure) and pre-test baseline QoL assessments. The Ideal Scale Approach was also used to assess changes in standards by comparing health and QoL expectancies between baseline and the end of the first hospitalization. Successive Comparison Approach was used to assess changes in values through the longitudinal assessment of the relative importance of EuroQOL dimensions. RESULTS: The results of this study showed that recalibration RS effects occurred early after the first hospitalization for 6/15 dimensions of QLQ-C30 (emotional, cognitive, fatigue, insomnia, appetite loss, diarrhea) and 2/8 of BR-23 (future perspective, systemic therapy side effects). Moreover, health and QoL expectancies changed between the baseline and the end of the first hospitalization, and changes in values were seen for the self-care and usual activities dimensions of the EuroQOL-EQ-5D. CONCLUSIONS: The occurrence of RS early after the first hospitalization suggests that it needs to be taken into account to interpret QoL changes in BC.
Authors: Carolyn E Schwartz; Rita Bode; Nicholas Repucci; Janine Becker; Mirjam A G Sprangers; Peter M Fayers Journal: Qual Life Res Date: 2006-09-26 Impact factor: 4.147
Authors: M A Sprangers; M Groenvold; J I Arraras; J Franklin; A te Velde; M Muller; L Franzini; A Williams; H C de Haes; P Hopwood; A Cull; N K Aaronson Journal: J Clin Oncol Date: 1996-10 Impact factor: 44.544
Authors: Jonathan Rees; Michael G Clarke; Dympna Waldron; Ciaran O'Boyle; Paul Ewings; Ruaraidh P MacDonagh Journal: Health Qual Life Outcomes Date: 2005-03-30 Impact factor: 3.186
Authors: Deborah B Crom; Zhenghong Li; Tara M Brinkman; Melissa M Hudson; Gregory T Armstrong; Joseph Neglia; Kirsten K Ness Journal: J Pediatr Oncol Nurs Date: 2014-07-15 Impact factor: 1.636
Authors: Mirelle Lagendijk; Elizabeth Mittendorf; Tari A King; Christopher Gibbons; Andrea Pusic; Laura S Dominici Journal: Oncologist Date: 2019-12-17
Authors: Rana El Haidari; Amelie Anota; Tienhan S Dabakuyo-Yonli; Francis Guillemin; Thierry Conroy; Michel Velten; Damien Jolly; Sylvain Causeret; Jean Cuisenier; Olivier Graesslin; Linda Abou Abbas; Virginie Nerich Journal: Qual Life Res Date: 2022-05-19 Impact factor: 3.440
Authors: Ahmad Ousmen; Thierry Conroy; Francis Guillemin; Michel Velten; Damien Jolly; Mariette Mercier; Sylvain Causeret; Jean Cuisenier; Olivier Graesslin; Zeinab Hamidou; Franck Bonnetain; Amélie Anota Journal: Health Qual Life Outcomes Date: 2016-12-03 Impact factor: 3.186
Authors: Marcus Lanza; Anke Bergmann; Maria Giseli da Costa Leite Ferreira; Suzana Sales de Aguiar; Ricardo de Almeida Dias; Karen de Souza Abrahão; Ester M Paltrinieri; Ruy G Martínez Allende; Mauro Figueiredo Carvalho de Andrade Journal: Int J Breast Cancer Date: 2015-12-30